Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
We analyze the prognostic value of the presenting features of a series of patients with symptomatic Waldenstrom's macroglobulinemia who were homogeneously treated. A total of 215 patients (119 males) with a median age of 62.6 years (range, 24.9 to 91.6) were retrospectively analyzed. The median overall follow-up was 57.6 months (range, 0.6 to 281): 58 (0.9 to 281) for living patients and 52.2 (0.6 to 261.3) for those who died. All patients were treated with alkylating agent-based chemotherapy. The overall median survival was 77.2 months, without significant differences based on the duration of the previous monoclonal gammopathy of undetermined significance (MGUS) phase. The multivariate Cox analysis performed on the whole population showed that age, hemoglobin level, and serum albumin level predicted survival. The addition of beta(2)-microglobulin, available in the subgroup of 60 patients diagnosed after 1990, in a Cox stepwise selection showed that this parameter was by far the main prognostic determinant. Application of the Dhodapkar, Morel, and Gobbi scoring systems to this population of patients showed that all three stratified the population into groups with significantly distinct prognoses. A prognostic index based on age, hemoglobin, and albumin is capable of identifying various groups of patients with different therapeutic needs.
Research Biotechnology Laboratories, and Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo, Pavia, Italy.
Giampaolo
G
Merlini
Luca
L
Baldini
Chiara
C
Broglia
Mario
M
Comelli
Maria
M
Goldaniga
Giovanni
G
Palladini
Giorgio Lambertenghi
GL
Deliliers
Paolo G
PG
Gobbi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis; D008258:Waldenstrom Macroglobulinemia / Q000097:blood* / Q000188:drug therapy / Q000401:mortality*
D018906:Antineoplastic Agents, Alkylating